H image acquisition using a non-ferromagnetic cuff in the non-dominant arm.Cytomegalovirus assayThe CMV IgG status of patients was evaluated using an inhouse enzyme-linked immunosorbent assay. A 96 well plate was coated with cell lysate purified from CMV-infected fibroblast cultures, with lysate from uninfected cells used as a negative control (50 mL/well diluted in coating buffer (0.2M sodium carbonate/0.2M sodium bicarbonate/pH 9.6) and incubated at 4uC for 16 hours). Samples were added in a 1:600 dilution in buffer (phosphate buffered saline (PBS)/1 bovine serum albumin/0.05 Tween20) together with standards to make a calibration curve (pooled plasma from three healthy CMV positive donors). Secondary antibody (anti-human IgG-horseradish peroxidase, Southern Biotech) was added after 30 minutes incubation at room Hydroxy Iloperidone custom synthesis temperature and washing with PBS/0.05 Tween20. Tetramethylbenzidine MedChemExpress I-CBP112 solution was added after a further 30 minutes/wash and incubated for 10 minutes at room temperature, protected from light. The reaction was stopped using 1M hydrochloric acid and the plate was read immediately using a microplate reader at absorbance 450 nm. Optical density was analysed using GraphPad PRISM (GraphPad Software, CA) and values attributable only to CMV IgG were calculated by subtracting control lysate values from that of the CMV lysates. A cut off of 10 arbitrary units was used to determine positive/ negative CMV IgG status.Methods Study design, setting and participantsPatients were prospectively recruited from renal clinics at the Queen Elizabeth Hospital Birmingham, UK. Patients were included if aged 18?0 years with CKD stages 2? (eGFR 15?89 ml/min/1.73 m2 estimated using the four-variable Modification of Diet in Renal Disease formula). Patients with a history or other evidence of angina, previous myocardial infarction, previous stroke, peripheral vascular disease, previous revascularisation procedure, heart failure, atrial fibrillation, moderate or severe cardiac valve disease, uncontrolled hypertension (mean daytime 24-hour ambulatory blood pressure (BP) .130/85 mmHg), hypercholesterolemia (total serum cholesterol .5.5 mmol/L) and diabetes mellitus were excluded. The West Midlands Research Ethics Committee approved the study and written informed consent was obtained from each participant.Blood pressure measurementsBrachial BP was recorded in the non-dominant arm in triplicate following 15 minutes of supine rest using a validated oscillometric sphygmomanometer (Dinamap ProCare 200, GE Healthcare, United Kingdom). All subjects underwent 24-hour ambulatory BP measurement (Meditech ABPM-04; PMS Instruments, Maidenhead, UK).Statistical analysesBaseline characteristics were assessed using standard descriptive statistics. Data distribution was tested using the KolmogorovSmirnov test. Data are presented as mean6standard deviation or median (interquartile range) for normally or non-normally distributed variables respectively. Variables not normally distributed were log transformed prior to analysis. Colinearity between variables was assessed by examining the variance inflation factor; a value .5 indicated colinearity. Linear regression was used to examine the relationships between measures of arterial stiffness and baseline demographic parameters. We utilized multivariable regression models to examine the relationship between arterial stiffness parameters and significant correlates on univariable analysis. A Type I error rate below 5 (P,0.05) was co.H image acquisition using a non-ferromagnetic cuff in the non-dominant arm.Cytomegalovirus assayThe CMV IgG status of patients was evaluated using an inhouse enzyme-linked immunosorbent assay. A 96 well plate was coated with cell lysate purified from CMV-infected fibroblast cultures, with lysate from uninfected cells used as a negative control (50 mL/well diluted in coating buffer (0.2M sodium carbonate/0.2M sodium bicarbonate/pH 9.6) and incubated at 4uC for 16 hours). Samples were added in a 1:600 dilution in buffer (phosphate buffered saline (PBS)/1 bovine serum albumin/0.05 Tween20) together with standards to make a calibration curve (pooled plasma from three healthy CMV positive donors). Secondary antibody (anti-human IgG-horseradish peroxidase, Southern Biotech) was added after 30 minutes incubation at room temperature and washing with PBS/0.05 Tween20. Tetramethylbenzidine solution was added after a further 30 minutes/wash and incubated for 10 minutes at room temperature, protected from light. The reaction was stopped using 1M hydrochloric acid and the plate was read immediately using a microplate reader at absorbance 450 nm. Optical density was analysed using GraphPad PRISM (GraphPad Software, CA) and values attributable only to CMV IgG were calculated by subtracting control lysate values from that of the CMV lysates. A cut off of 10 arbitrary units was used to determine positive/ negative CMV IgG status.Methods Study design, setting and participantsPatients were prospectively recruited from renal clinics at the Queen Elizabeth Hospital Birmingham, UK. Patients were included if aged 18?0 years with CKD stages 2? (eGFR 15?89 ml/min/1.73 m2 estimated using the four-variable Modification of Diet in Renal Disease formula). Patients with a history or other evidence of angina, previous myocardial infarction, previous stroke, peripheral vascular disease, previous revascularisation procedure, heart failure, atrial fibrillation, moderate or severe cardiac valve disease, uncontrolled hypertension (mean daytime 24-hour ambulatory blood pressure (BP) .130/85 mmHg), hypercholesterolemia (total serum cholesterol .5.5 mmol/L) and diabetes mellitus were excluded. The West Midlands Research Ethics Committee approved the study and written informed consent was obtained from each participant.Blood pressure measurementsBrachial BP was recorded in the non-dominant arm in triplicate following 15 minutes of supine rest using a validated oscillometric sphygmomanometer (Dinamap ProCare 200, GE Healthcare, United Kingdom). All subjects underwent 24-hour ambulatory BP measurement (Meditech ABPM-04; PMS Instruments, Maidenhead, UK).Statistical analysesBaseline characteristics were assessed using standard descriptive statistics. Data distribution was tested using the KolmogorovSmirnov test. Data are presented as mean6standard deviation or median (interquartile range) for normally or non-normally distributed variables respectively. Variables not normally distributed were log transformed prior to analysis. Colinearity between variables was assessed by examining the variance inflation factor; a value .5 indicated colinearity. Linear regression was used to examine the relationships between measures of arterial stiffness and baseline demographic parameters. We utilized multivariable regression models to examine the relationship between arterial stiffness parameters and significant correlates on univariable analysis. A Type I error rate below 5 (P,0.05) was co.
